Online inquiry

IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15977MR)

This product GTTS-WQ15977MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat IL31 gene. The antibody can be applied in Feline atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_011287838.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 105261056
UniProt ID A0A337S7E6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15977MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2890MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ6202MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ8155MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15587MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ11387MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ11953MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ11246MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ4952MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW